Hematological malignancies bank
Collection of biological material left over samples from patients diagnosed with hematological malignancies (myelodysplastic syndromes, myeloproliferative diseases, acute myeloblastic leukemia, acute lymphoblastic leukemia, multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin's lymphoma) as well as information associated with said samples.
The historical origin of this collection is the left over material from diagnosed patients.
Patient eligibility criteria
Eligible patients for recruitment must accomplish the following criteria:
- Patients must have been diagnosed with one of the hematological malignancies according to the standardized definitions and guides from international scientific societies and have a clinical indication for biopsy samples or extirpation (minor or major surgery).
- Sign the informed consent form.
Sample types collected
Peripheral blood, bone marrow, and cell suspensions obtained by tissue disaggregation.
Scientific purpose and interest
To obtain samples from cancer patients and make them available to the scientific community with the purpose of facilitating, promoting and developing national and international scientific research regarding different types of hematological conditions.
- DNA bank for cardiovascular diseases
- Cerebral infarction (ICTUS) sample bank
- FORTIAM, acute myocardial infarction sample collection
- DNA bank for oncological diseases
- Left over diagnose sample bank
- Bank of samples from influenza A (H1N1) patients
- Bank of lung disease samples (Lung Biobank Platform)
- Cryopreserved tumour bank
- Collection Alzheimer and families (Alfa Study)
- ERyME: Sample collection from patients with rheumatic or muscle-skeletal disease
- GLOSEN: Glomerular diseases sample collection